KPRX - Kiora Pharmaceuticals, Inc. Total Debt to Capital

This price chart for Kiora Pharmaceuticals (KPRX), which assists in the basic asset valuation, demonstrates a debt load of 0.02. The business relies on patent protection for rare retinal drugs, ensuring stable demand and high yields. However, political fragmentation and trade restrictions hinder international testing and equipment deliveries. Meanwhile, orphan drug status from the FDA and EMA protects the market niche of KIO-301.

For Kiora Pharmaceuticals (KPRX), whose operations are focused on costly clinical trials without current revenue, the total debt-to-equity ratio serves as an indicator of financial autonomy. This metric compares total liabilities to equity, demonstrating the degree of dependence on creditors and the business's resilience to market shocks during periods of awaiting drug development results.